Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PRIMAXIN is a fixed-dose combination of imipenem (a broad-spectrum carbapenem beta-lactam antibiotic) and cilastatin sodium (a renal dipeptidase inhibitor that prevents imipenem degradation). It is administered intramuscularly for serious bacterial infections caused by susceptible aerobic and anaerobic gram-positive and gram-negative organisms. The drug works by inhibiting bacterial cell wall synthesis through beta-lactam activity, with cilastatin enhancing imipenem bioavailability.
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a mature brand team focused on retention rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PRIMAXIN offers limited growth trajectory given its LOE-approaching status and minimal linked job openings; roles are primarily maintenance-focused within commercial and medical affairs. This assignment is best suited for professionals seeking expertise in mature brand management, formulary defense, or legacy product optimization rather than launch or expansion experience.
Worked on PRIMAXIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo